Actelion study leader says Opsumit missed PAH study endpoint

ZURICH, Jan 23 (Reuters) - Actelion's Opsumit drug

missed a primary endpoint in a study of patients with pulmonary

arterial hypertension due to Eisenmenger Syndrome, a doctor

involved in leading the trial said in a statement issued by the

Swiss drugmaker on Monday.

Read more